Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Schering-Plough claims felbamate metabolite

April 5, 1996

Roche Bioscience claims antiemetic drugs

April 5, 1996

SYM-2206 for seizure prevention

April 5, 1996

Anticonvulsants claimed by Bristol-Myers Squibb

April 5, 1996

Stanford investigators identify epilepsy gene

April 5, 1996

Synthelabo reports antidepressants

April 5, 1996

5-HT1A/5-HT2C receptor ligands from Roche

April 5, 1996

New anthranilide in phase I at Glaxo Wellcome

April 5, 1996

L-745870: D4 antagonist for schizophrenia

April 5, 1996

New antipsychotic drug in phase I at P&U

April 5, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 27, 2026.
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...